suMMARY A double blind cross-over study of eight patients with familial hypokalaemic periodic paralysis was made to assess the influence of acetazolamide on muscle strength. All patients had a reduced interictal muscle fibre conduction velocity. Five patients had no attacks at the time of the study. One patient withdrew from the study because of an adverse reaction. The muscle strength of 11 muscle groups was measured with a hand-held dynamometer. The sum of force improved significantly in the seven patients (mean increase: 17%, p < 005; 95% confidence interval: 7-2-26-8%). Endurance tests showed an improvement in the performance of 30 full kneebends. Surface EMG measurement showed no change in the muscle fibre conduction velocity or power spectra during treatment. The integrated EMG showed a (non significant) mean increase of 21%.
Primary hypokalaemic periodic paralysis is characterised by different kinds of muscle weakness. The paralytic attacks are the most well known. In addition a permanent muscle weakness (PMW) has been described. This can be the result of the destruction of muscle tissue due to myopathy.1 Alternatively, "abortive attacks" occur, that is, long lasting episodes with fluctuating weakness.2 3 As this weakness can be reversed by acetazolamide, these "abortive attacks" are probably due to a functional disturbance of the muscle membrane.
We have found4 that the mean strength of affected persons with hypokalaemic periodic paralysis is lower than the mean of normals. This implies that the cause of this "less than average strength" could be the same as the cause of abortive attacks. To test this hypothesis the influence of acetazolamide on the interictal strength in eight patients was assessed.
Patients and methods
All patients were members of a large family suffering from hypokalaemic periodic paralysis described in an earlier report.4 The main inclusion criterion was the finding of a reduced interictal muscle fibre conduction velocity (MFCV). The methods and the control group have been fully described.4 Briefly, the MFCV was measured with two patients and patients nos 3, 4 and 6, who had never suffered from paralytic attacks, all complained of lack of strength in general and stiffness and pain of their upper legs during cold days and after rest.
Acetazolamide (3 x 125 mg daily) and placebo (lactose) were given in randomised order according to a cross-over design for 2 weeks each. The patients were seen weekly at the same time by the same blinded observer experienced in the use of the dynamometer. At every visit blood samples were taken to measure the serum electrolytes, venous pH, pCO2, HC03-, and the muscle enzymes creatine kinase and myoglobin.
Muscle strength of 1 1 muscle groups (see fig 1) 
Discussion
The results confirm our hypothesis that acetazolamide improves muscle strength in patients with hypokalaemic periodic paralysis. The benefit of the medication was such that six of the seven patients who finished the trial continued to use acetazolamide. Remarkably, the most pronounced improvement of strength was generally seen in the limb-girdle muscles (fig 1) . These are also preferentially affected in the myopathy of hypokalaemic periodic paralysis. 7 Though attention has always been drawn to the paralytic attacks as the consequence of the membrane disturbance, this study shows another clinical expression: a permanent muscle weakness which was partially reversible in six of the patients without concomitant attacks. The acid base equilibrium and chloride concentration changed significantly during the medication resulting in a metabolic acidosis. Though supported by some,"0 it is not likely that this change is related to the improvement of the muscle strength, because the influence of acetazolamide on the acid base equilibrium is maximal within several days" and the improvement of muscle strength continued during the second week of therapy (fig 2) . This is in accordance with Buruma,'2 who found no relation between electrolyte changes and the beneficial effect on attack frequency.
We conclude that acetazolamide improves the muscle strength in patients with hypokalaemic periodic paralysis even in the absence of paralytic attacks, probably by stabilising the muscle membrane. 
